The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma .
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
FDA Approves Liso-Cel to Treat R/R Mantle Cell Lymphoma ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.